A Michigan Medicine-led study, led by Jordan K. Schaefer, M.D., M.Sc., clinical associate professor of internal medicine-hematology at the University of Michigan Medical School, suggests that reducing the dose of popular blood thinners (rivaroxaban and apixaban) after six months may decrease the risk of bleeding and hospital visits without increasing the likelihood of recurrent blood clots. The study supports 2021 guidelines recommending reduced dosing for long-term blood clot management, although further randomized trials are needed to confirm the findings.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.